



12-0803

AF/1600

Docket No. 1151-4153US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chang Yi WANG et al

Group Art Unit: 1644

Serial No.: 09/701,623

Examiner: Huynh, Phuong N., Ph.D.

Filed: June 21, 1999

For: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF ALLERGY

EXPRESS MAIL CERTIFICATE

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
DEC 10 2003
TECH CENTER 1600/2900

Express Mail Label No.: EV 357 836 788US

Date of Deposit: December 5, 2003

I hereby certify that the following attached paper(s) and/or fee

1. Summary of Record Interview under 37 CFR 1.133;
2. Return postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Shen

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Chang Yi WANG et al
Serial No : 09/701,623
Int. Filing Date : June 21, 1999
For : PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT
OF ALLERGY
Group Art Unit : 1644
Examiner : Huynh, Phuong N., Ph.D.

Mail Stop: AF
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RECEIVED
DEC 13 2003
TECH CENTER 1600/2900

SUMMARY OF RECORD OF INTERVIEW
PURSUANT TO 37 C.F.R. §1.133

Sir:

This is to summarize the record of the interview conducted by telephone on November 21, 2003 to comply with 37 C.F.R. §1.133. The participants of the interview were Christina Chan, Supervisory Examiner, and the applicant's representative, the undersigned. The time spent in the preparation of the interview and the interview itself, especially when it was done after working hours, and the kind courtesy extended by the Examiner's Supervisor is deeply appreciated.

No exhibits were presented at the interview. All of the issues raised by the Examiner in the office action dated August 27, 2003 were discussed. The following issues were resolved.

1. To overcome the rejection under §112, first and second paragraph, Claim 29 is to be rewritten without using the term "AA413-AA435 of the epsilon heavy chain of a mammalian IgE". This is to be replaced by the wording used in originally filed claim 1:

An IgE-CH3 domain antigen peptide of between about 25 and about 29 amino acids in length containing two cysteine residues separated by about 23 amino acids residues, selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 84, or an immunologically functional analog thereof, wherein from one to four of the residues in SEQ ID NO: 5 is conservatively substituted or deleted.

The recital of an immunologically functional analog of the recited sequences with one to four conservative substitutions or deletions is acceptable.

2. The restriction requirement is accepted to expedite allowance.

The remaining issue of the effective date of the present application is to be argued by presenting evidence showing that the applicant is entitled to the filing date of the parent application Serial No. 09/100,287 as stated on the Filing Receipt.

Respectfully submitted,

Dated: December 5, 2003



Maria C.H. Lin
Registration No. 29,323

CORRESPONDENCE ADDRESS:
MORGAN & FINNEGAN LLP
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile
Direct Line: 212-415-8745